Investigational drug · Phase 3
Astegolimab
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease (COPD).
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
1 still active
All registered trials
8
Any phase or sponsor naming "Astegolimab"
First trial start
2021
Oct 5, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Astegolimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Chronic Obstructive Pulmonary Disease
- Chronic Obstructive Pulmonary Disease (COPD)
Approved drugs for the same conditions: COPD · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Astegolimab" as an intervention, largest first.
- A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD)Pivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05878769 · 2,000 participants (planned) · Start Jun 28, 2023 · Primary completion Jun 30, 2027
Drug: Astegolimab · For: Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Dothan, Alabama; Jasper, Alabama · 480 sites in all
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT05595642 · 1,380 participants · Start Dec 29, 2022 · Primary completion Jun 24, 2025
Drug: Astegolimab; Placebo · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Dothan, Alabama; Glendale, Arizona · 348 sites in all
- A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary DiseasePivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05037929 · 1,334 participants · Start Oct 5, 2021 · Primary completion Feb 24, 2025
Drug: Astegolimab; Placebo · For: Chronic Obstructive Pulmonary Disease
Sites: Dothan, Alabama; Jasper, Alabama; Mobile, Alabama · 193 sites in all
- A Study to Assess the Efficacy and Safety of MSTT1041A in Participants With Uncontrolled Severe AsthmaPivotal-lookingCompleted
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT02918019 · 517 participants · Start Sep 20, 2016 · Primary completion Apr 5, 2019
Drug: MSTT1041A; Placebo · For: Asthma
Sites: Birmingham, Alabama; Tucson, Arizona; Bakersfield, California · 138 sites in all
- A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 PneumoniaPivotal-lookingCompleted
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04386616 · 396 participants · Start Jun 2, 2020 · Primary completion Jan 8, 2021
Drug: MSTT1041A; MSTT1041A-matched Placebo and 2 more · For: COVID-19 Pneumonia
Sites: Little Rock, Arkansas; Chula Vista, California; La Mesa, California · 41 sites in all
University of LeicesterAcademic, hospital or other
NCT03615040 · 81 participants · Start Oct 11, 2018 · Primary completion May 29, 2020
Drug: MSTT1041A; Placebo · For: COPD Exacerbation
Sites: Leicester, United Kingdom
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT06462118 · 78 participants · Start Jun 17, 2024 · Primary completion Oct 22, 2024
Drug: Astegolimab · For: Healthy Volunteers
Sites: Daytona Beach, Florida; Dallas, Texas; Madison, Wisconsin
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT03747575 · 65 participants · Start Feb 6, 2019 · Primary completion Mar 11, 2020
Drug: MSTT1041A; Placebo · For: Atopic Dermatitis
Sites: Birmingham, Alabama; Los Angeles, California; Colorado Springs, Colorado · 21 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Reimagining COPD treatment: are biologics the next frontier?
Rogliani P, De Guido I, Gholamalishahi S, et al. · Expert Opin Pharmacother 2026
- Understanding the roles of interleukin-33: is there promise for therapeutic targeting?
Gao X, Yu Y, Zhong S, et al. · Expert Opin Ther Targets 2026
- Updates in COPD Management: From Inflammatory Pathways to Targeted Therapies.
Raman S, Rahman S, Polverino F, et al. · Eur J Clin Invest 2026
- Efficacy of Biologics in Patients with Moderate to Very Severe COPD: A Systematic Review.
Brightling CE, Rabe KF, Singh D, et al. · Int J Chron Obstruct Pulmon Dis 2026
- Astegolimab in COPD: success or failure?
Singh D, Dransfield M · Am J Respir Crit Care Med 2026
- Astegolimab for chronic obstructive pulmonary disease with frequent exacerbations: pooled analysis of the ALIENTO and ARNASA trials.
Wedzicha JA, Agustí À, Brightling CE, et al. · Am J Respir Crit Care Med 2026
Also in development for Chronic Obstructive Pulmonary Disease
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
- VerducatibBI 1291583Phase 34 trials
Boehringer Ingelheim · Bronchiectasis, Chronic Obstructive Pulmonary Disease
- CM326Phase 33 trials
CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Moderate to Severe Asthma
- TQC3721 forPhase 33 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Chronic Obstructive Pulmonary Disease, Pulmonary Disease, Chronic Obstructive
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Roche (Genentech).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.